NEWS

Genedata provides Expressionist platform to Eisai Research Institute

Genedata has announced an agreement with the Eisai Research Institute (ERI) for the company’s Genedata Expressionist biomarker discovery platform.

Genedata Expressionist is a modular computational platform for biomarker discovery that integrates transcriptomics, proteomics and metabolomics data within a single enterprise software system. With sophisticated high-throughput data processing and automated workflows for quality assessment, statistical analysis and interpretation functionalities, the platform provides a single-point-of-access for all experimental data, including sample information, raw and pre-processed data, analysis results and documentation with reports.

Jens Hoefkens, managing director of Genedata, said: ‘We are very pleased to be working with the Eisai Research Institute in meeting its bio-IT infrastructure needs for biomarker validation. As the latest of an increasing series of Expressionist installations, we view the institute’s choice as further validation of Expressionist’s appeal to researchers seeking a common platform of tools and applications for biomarker identification with stringent quality control and open data sharing.’

 

Twitter icon
Google icon
Del.icio.us icon
Digg icon
LinkedIn icon
Reddit icon
e-mail icon
Feature

Gemma Church finds out how astronomers are using simulations to investigate the extremities of our universe

Feature

Turning data into scientific insight is not a straightforward matter, writes Sophia Ktori

Feature

The Leibniz Supercomputing Centre (LRZ) is driving the development of new energy-efficient practices for HPC, as Robert Roe discovers

Feature

William Payne investigates the growing trend of using modular HPC, built on industry standard hardware and software, to support users across a range of both existing and emerging application areas

Feature

Robert Roe looks at developments in crash testing simulation – including larger, more intricate simulations, the use of optimisation software, and the development of new methodologies through collaboration between ISVs, commercial companies, and research organisations